A Clinical Trial of KT07 Capsule in the U.S.A

Exclusion Criteria

• •1. Subjects with severe influenza virus infection requiring inpatient treatment.
• •2. Subjects with concurrent infections requiring systemic antimicrobial and/or antiviral therapy at the time of screening.
• •3. Subjects who have any of the following documented conditions: uncontrolled hypertension (systolic blood pressure \> 140 mm Hg or diastolic blood pressure \> 90 mm Hg), diabetes, asthma (any current or recent, not childhood if resolved), COPD (any), cardiac, hepatic, renal (including eGFR\<60) and hematopoietic disorders, bleeding tendency or hemorrhagic disease, neurological system disease, compromised immune system (including patients receiving immunosuppressant therapy, or those with cancer within the past 5 years or human immunodeficiency virus \[HIV\] infection), endocrine disorders (including thyroid disorders).
• •4. Subjects with anatomical nasal obstruction or gross anatomical abnormalities. For example, nasal polyps or significant nasal septal deviation.
• •5. Clinically obese subjects with BMI≥40.
• •6. Subjects with recent history (within 1 year) of alcoholism or substance abuse.
• •7. Received influenza vaccine within 21 days.
• •8. Participation in other clinical trial within 1 month, or during the study.
• •9. Pregnant or breast-feeding female subjects
• •10. Allergy or known allergy to components of study medication.
• •11. Subjects who took a monoamine oxidase inhibitor (MAOI) within 2 weeks prior to enrollment.
• •12. Previous history of difficulty swallowing capsules.
• •13. Any other associated disease or condition which, in the opinion of the investigator, might restrict or impede participation in the study or affect the study results.